211 related articles for article (PubMed ID: 2045206)
21. Effect of a bovine hemoglobin preparation on the response of the FSaIIC fibrosarcoma to chemotherapeutic alkylating agents.
Teicher BA; Herman TS; Hopkins RE; Menon K
J Cancer Res Clin Oncol; 1992; 118(2):123-8. PubMed ID: 1735732
[TBL] [Abstract][Full Text] [Related]
22. Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells.
Ayash L; Korbut T; Herman TS; Teicher BA
Cancer Lett; 1991 Dec; 61(1):7-14. PubMed ID: 1764699
[TBL] [Abstract][Full Text] [Related]
23. The interaction of cisplatin plus etoposide with radiation +/- hyperthermia.
Pfeffer MR; Teicher BA; Holden SA; al-Achi A; Herman TS
Int J Radiat Oncol Biol Phys; 1990 Dec; 19(6):1439-47. PubMed ID: 2262368
[TBL] [Abstract][Full Text] [Related]
24. Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo.
Sotomayor EA; Teicher BA; Schwartz GN; Holden SA; Menon K; Herman TS; Frei E
Cancer Chemother Pharmacol; 1992; 30(5):377-84. PubMed ID: 1505076
[TBL] [Abstract][Full Text] [Related]
25. Protection of bone-marrow granulocyte-macrophage colony-forming units in mice bearing in vivo alkylating-agent-resistant EMT-6 tumors.
Teicher BA; Chatterjee D; Liu JT; Holden SA; Ara G
Cancer Chemother Pharmacol; 1993; 32(4):315-9. PubMed ID: 8324874
[TBL] [Abstract][Full Text] [Related]
26. Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model.
Eder JP; Teicher BA; Holden SA; Cathcart KN; Schnipper LE
J Clin Invest; 1987 May; 79(5):1524-8. PubMed ID: 3033027
[TBL] [Abstract][Full Text] [Related]
27. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
[TBL] [Abstract][Full Text] [Related]
28. Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo.
Herman TS; Teicher BA; Coleman CN
Cancer Res; 1990 Aug; 50(16):5055-9. PubMed ID: 2379171
[TBL] [Abstract][Full Text] [Related]
29. High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial.
Peters WP; Eder JP; Henner WD; Schryber S; Wilmore D; Finberg R; Schoenfeld D; Bast R; Gargone B; Antman K
J Clin Oncol; 1986 May; 4(5):646-54. PubMed ID: 3517240
[TBL] [Abstract][Full Text] [Related]
30. In vivo modulation of several anticancer agents by beta-carotene.
Teicher BA; Schwartz JL; Holden SA; Ara G; Northey D
Cancer Chemother Pharmacol; 1994; 34(3):235-41. PubMed ID: 8004757
[TBL] [Abstract][Full Text] [Related]
31. Pentoxifylline potentiates the antitumor effect of cisplatin and etoposide on human lung cancer cell lines.
Ohsaki Y; Ishida S; Fujikane T; Kikuchi K
Oncology; 1996; 53(4):327-33. PubMed ID: 8692539
[TBL] [Abstract][Full Text] [Related]
32. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR
Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926
[TBL] [Abstract][Full Text] [Related]
33. Minocycline as a modulator of chemotherapy and hyperthermia in vitro and in vivo.
Teicher BA; Holden SA; Liu CJ; Ara G; Herman TS
Cancer Lett; 1994 Jul; 82(1):17-25. PubMed ID: 8033065
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies.
Motta MR; Mangianti S; Rizzi S; Ratta M; Campanini E; Fortuna A; Fogli M; Tura S; Lemoli RM
Exp Hematol; 1997 Nov; 25(12):1261-9. PubMed ID: 9357970
[TBL] [Abstract][Full Text] [Related]
35. Modification of alkylating agent cytotoxicity by cisplatin.
Horsman MR; Hirst DG; Brown DM; Brown JM
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1669-73. PubMed ID: 6541216
[TBL] [Abstract][Full Text] [Related]
36. Preclinical studies and clinical correlation of the effect of alkylating dose.
Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of lonidamine combined with different DNA-damaging agents in the treatment of the MX-1 tumor xenograft.
Pratesi G; De Cesare M; Zunino F
Cancer Chemother Pharmacol; 1996; 38(2):123-8. PubMed ID: 8616901
[TBL] [Abstract][Full Text] [Related]
38. Interaction of D,L- and D-tetraplatin with hyperthermia in vitro and in vivo.
Epelbaum R; Teicher BA; Holden SA; Ara G; Varshney A; Herman TS
Eur J Cancer; 1992; 28A(4-5):794-800. PubMed ID: 1524897
[TBL] [Abstract][Full Text] [Related]
39. Sensitivity of normal mouse marrow and RIF-1 tumour to hyperthermia combined with cyclophosphamide or BCNU: a lack of therapeutic gain.
Honess DJ; Bleehen NM
Br J Cancer; 1982 Aug; 46(2):236-48. PubMed ID: 6758828
[TBL] [Abstract][Full Text] [Related]
40. Synergism between alkylating agent and cis-platin with moderate local hyperthermia: the effect of multidrug chemotherapy in an animal system.
Matsushita S; Reynolds R; Urano M
Int J Hyperthermia; 1993; 9(2):285-96. PubMed ID: 8468510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
